Clinical outcomes and direct hospital costs of
reduced-intensity allogeneic transplantation in chronic myeloid
leukemia

J 2006

Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia

KREJČÍ, Marta, Jiří MAYER, Michael DOUBEK, Yvona BRYCHTOVÁ, Z POSPÍŠIL et. al.

Basic information

Original name

Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia

Authors

Edition

Bone Marrow Transplantation, London, Nature Publishing Group, 2006, 0268-3369

Other information

Type of outcome

Article in a journal

Confidentiality degree

is not subject to a state or trade secret

Impact factor

Impact factor: 2.621

Organization unit

Faculty of Medicine

UT WoS

000241101900003

Keywords (in Czech)

CML, alogenní transplantace kmenových buněk, imatinib

Keywords in English

chronic myeloid leukemia; allogeneic stem cell transplantation; imatinib

Changed: 3/11/2010 14:58, prof. MUDr. Zdeněk Ráčil, Ph.D.

Abstract

V originále

A reduced-intensity conditioning allogeneic stem cell transplantation was given to 19 patients (aged 15 - 59 years) in the first chronic phase and one patient in the accelerated phase with chronic myeloid leukemia (CML) after a regimen consisting of fludarabine (Flu), busulfan (Bu) and ATG Fresenius. The median follow-up was 27 months. The incidence of acute and chronic graft-versus-host disease (GvHD) was 55 and 75%, respectively. Two patients (10%) died from GvHD. Fourteen (70%) patients achieved molecular remission. Additional post-transplant intervention (donor lymphocyte infusion, imatinib) was necessary, however, in 10 patients (50% of the patients; non-achievement of stable molecular remission or later relapses). The total direct cost of the transplantation treatment for all of the patients came to 1 572 880 euro. If the patients had been treated with imatinib and followed-up with the same time period as they were following a transplantation, the direct cost of the imatinib treatment would have been 2 005 117 euro. The transplantation treatment appears to be less expensive after approximately 2 years of follow-up. Flu+Bu+ATG is a low-toxicity regimen for patients with CML. However, a close follow-up is necessary and about 50% of the patients require further therapeutic intervention.

Cite

KREJČÍ, Marta, Jiří MAYER, Michael DOUBEK, Yvona BRYCHTOVÁ, Z POSPÍŠIL, Zdeněk RÁČIL, Dana DVOŘÁKOVÁ, Martina LENGEROVÁ, Ondřej HORKÝ, Zdeněk KOŘÍSTEK, T DOLEŽAL and Jiří VORLÍČEK. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. Bone Marrow Transplantation. London: Nature Publishing Group, 2006, vol. 38, No 7, p. 483-491. ISSN 0268-3369.

@article{838464,
   author = {Krejčí, Marta and Mayer, Jiří and Doubek, Michael and Brychtová, Yvona and Pospíšil, Z and Ráčil, Zdeněk and Dvořáková, Dana and Lengerová, Martina and Horký, Ondřej and Kořístek, Zdeněk and Doležal, T and Vorlíček, Jiří},
   article_location = {London},
   article_number = {7},
   keywords = {chronic myeloid leukemia; allogeneic stem cell transplantation; imatinib},
   issn = {0268-3369},
   journal = {Bone Marrow Transplantation},
   title = {Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia},
   volume = {38},
   year = {2006}
}

TY  - JOUR
ID  - 838464
AU  - Krejčí, Marta - Mayer, Jiří - Doubek, Michael - Brychtová, Yvona - Pospíšil, Z - Ráčil, Zdeněk - Dvořáková, Dana - Lengerová, Martina - Horký, Ondřej - Kořístek, Zdeněk - Doležal, T - Vorlíček, Jiří
PY  - 2006
TI  - Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia
JF  - Bone Marrow Transplantation
VL  - 38
IS  - 7
SP  - 483-491
EP  - 483-491
PB  - Nature Publishing Group
SN  - 02683369
KW  - chronic myeloid leukemia
KW  - allogeneic stem cell transplantation
KW  - imatinib
N2  - A reduced-intensity conditioning allogeneic stem cell transplantation was given to 19 patients (aged 15 - 59 years) in the first chronic phase and one patient in the accelerated phase with chronic myeloid leukemia (CML) after a regimen consisting of fludarabine (Flu), busulfan (Bu) and ATG Fresenius. The median follow-up was 27 months. The incidence of acute and chronic graft-versus-host disease (GvHD) was 55 and 75%, respectively. Two patients (10%) died from GvHD. Fourteen (70%) patients achieved molecular remission. Additional post-transplant intervention (donor lymphocyte infusion, imatinib) was necessary, however, in 10 patients (50% of the patients; non-achievement of stable molecular remission or later relapses). The total direct cost of the transplantation treatment for all of the patients came to 1 572 880 euro. If the patients had been treated with imatinib and followed-up with the same time period as they were following a transplantation, the direct cost of the imatinib treatment would have been 2 005 117 euro. The transplantation treatment appears to be less expensive after approximately 2 years of follow-up. Flu+Bu+ATG is a low-toxicity regimen for patients with CML. However, a close follow-up is necessary and about 50% of the patients require further therapeutic intervention.
ER  -

KREJČÍ, Marta, Jiří MAYER, Michael DOUBEK, Yvona BRYCHTOVÁ, Z POSPÍŠIL, Zdeněk RÁČIL, Dana DVOŘÁKOVÁ, Martina LENGEROVÁ, Ondřej HORKÝ, Zdeněk KOŘÍSTEK, T DOLEŽAL and Jiří VORLÍČEK. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. \textit{Bone Marrow Transplantation}. London: Nature Publishing Group, 2006, vol.~38, No~7, p.~483-491. ISSN~0268-3369.

Přehled o publikaci